Table 3.
Meta‐Regression Analyses
Outcome | Covariates | |||||
---|---|---|---|---|---|---|
Age | Male Sex | BMI | Diabetes Mellitus | Baseline LDL | ||
TC | Z value | −2.82 | −0.95 | 2.30 | −0.22 | 2.48 |
P value | 0.005 | 0.343 | 0.021 | 0.822 | 0.013 | |
LDL‐C | Z value | −4.41 | −2.67 | 4.32 | 0.13 | 4.41 |
P value | <0.001 | 0.007 | <0.001 | 0.894 | <0.001 | |
Non–HDL‐C | Z value | −3.28 | −1.51 | 2.62 | 0.08 | 3.00 |
P value | 0.001 | 0.131 | 0.009 | 0.935 | 0.003 | |
ApoB | Z value | −2.42 | −1.13 | 2.12 | 0.32 | 2.01 |
P value | 0.015 | 0.259 | 0.033 | 0.746 | 0.044 | |
hs‐CRP | Z value | −3.23 | −0.87 | 2.46 | −0.96 | 2.56 |
P value | 0.001 | 0.385 | 0.014 | 0.338 | 0.011 |
Impact of age, male sex, BMI, diabetes mellitus, and baseline LDL‐C on the difference in reduction of TC, LDL‐C, non–HDL‐C, ApoB, and hs‐CRP between patients receiving bempedoic acid and control treatment group. ApoB indicates apolipoprotein B; BMI, body mass index; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; LDL‐C, LDL cholesterol; and TC, total cholesterol.